| Literature DB >> 29606308 |
Hanna Mendes Levitin1, Jinzhou Yuan1, Peter A Sims2.
Abstract
Intratumoral heterogeneity is among the greatest challenges in precision cancer therapy. However, developments in high-throughput single-cell RNA sequencing (scRNA-seq) may now provide the statistical power to dissect the diverse cellular populations of tumors. In the future these technologies might inform the selection of targeted combination therapies and enrollment criteria for clinical trials.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29606308 PMCID: PMC5993208 DOI: 10.1016/j.trecan.2018.02.003
Source DB: PubMed Journal: Trends Cancer ISSN: 2405-8025